DOCSLIB.ORG

Table of Contents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Table of Contents TheJournalof VOLUME271 PHARMACOLOGY NUMBER 3 AND EXPERIMENTAL THERAPEUTICS Contents ANTI-INFLAMMATORIES Lecithinized Superoxide Dismutase Enhances Its R. Igarashi, J. Hoshino, A. Ochiai, 1672 Pharmacologic Potency by Increasing Its Cell Membrane Y. Morizawa and Y. Mizushima Affinity ANALGESICS Role of Endogenous Cholecystokinin in the Facilitation of Mu- Florence Noble, Claire Smadja and 1127 Mediated Antinociception by Delta.Opioid Agonists Bernard P. Roques Downloaded from GBR12909 Attenuates Cocaine-Induced Activation of Michael H. Baumann, George U. Char, 1216 Mesolimbic Dopamine Neurons in the Rat Brian R. Dc Costa, Kenner C. Rice and Richard B. Rothman Substance P N-Terminal Metabolites and Nitric Oxide Mediate Julie S. Kreeger, Kelley F. Kitto and 1281 Capsaicin-Induced Antinociception in the Adult Mouse Alice A. Larson Antinociceptive Actions of Dexmedetomidine and the Kappa- Juhana J. Idanpaan-Heikkila, Eija A. Kalso 1306 jpet.aspetjournals.org Opioid Agonist U.5O,488H against Noxious Thermal, and Timo Seppala Mechanical and Inflammatory Stimuli Involvement of NMDA Receptors in Naloxone-Induced Rustam Yu. Yukhananov and 1365 Contractions of the Isolated Guinea Pig ileum after Alice A. Larson Preincubation with Morphine Development of Cross-Tolerance between - Fang Fan, David R. Compton, Susan Ward, 1383 Tetrahydrocannabinol, CP 55,940 and WIN 55,212 Lawrence Melvin and Billy R. Martin at ASPET Journals on October 2, 2021 Antinociceptive and Response Rate-Altering Effects of Kappa Raymond C. Pitts and Linda A. Dykstra 1501 Opioid Agonists, Spiradoline, Enadoline and U69,593, Alone and in Combination with Opioid Antagonists in Squirrel Monkeys The Influence of Pharmacogenetics on Opioid Analgesia: Jim Cleary, Gerd Mikus, Andrew Somogyi 1528 Studies with Codeine and Oxycodone in the Sprague-Dawley/ and Felix Bochner Dark Agouti Rat Model Selective Antagonism of Opioid Analgesia by a Sigma System Chih-Cheng Chien and 1583 Gavril W. Pasternak Binding Affinity and Selectivity of Opioids at Mu, Delta and Paul J. Emmerson, Man-ru Liu, 1630 Kappa Receptors in Monkey Brain Membranes James H. Woods and Fedor Medzihradsky Increased Plasma Atrial Natriuretic Peptide after Acute Pascal Guillaume, Jolanta Gutkowska and 1656 Injection of Alcohol in Rats Christina Gianoulakis High Affinity Cocaine Recognition Sites on the Dopamine Julie K. Staley, W. Lee Hearn, 1678 Transporter are Elevated in Fatal Cocaine Overdose Victims A. James Ruttenber, C. V. Wetli and Deborah C. Mash Analysis of Delta-Opioid Receptor Activities Stably Expressed P. Y. Law, T. M. McGinn, M. J. Wick, 1686 in CHO Cell Lines: Function of Receptor Density? L. J. Erikson, C. Evans and H. H. Loh AUTONOMIC PHARMACOLOGY Characterization of Alpha-i Adrenoceptor Subtypes in Human Aaron S. Goetz, Michael W. Lutz, 1228 and Canine Prostate Membranes Thomas J. Rimele and David L. Saussy, Jr. MEN 10,627, a Novel Polycydic Peptide Antagonist of Carlo Alberto Maggi, Mara Astolfi, 1489 Tachykinin NK2 Receptors Sandro Giuliani, Cristina Goso, Stefano Manzini, Stefania Meini, Riccardo Patacchini, Vincenzo Pavone, Carlo Pedone, Laura Quartara, Anna Rita Renzetti and Antonio Giachetti This One IDIIIIIUIIUIIIIN1 IIUUDINon:enu continued on ii J28R-SHB-6UQ9 Contents continuedfro.n i Stimulatory Pathways and Sites of Action of Intrathecally Imran M. Khan, Palmer Taylor and 1550 Administered Nicotinic Agents Tony L Yaksh Muscarinlc Receptors Involved in Modulation of Miguel A. Casado, M. Angeles Sevifia, 1638 Norepinephrine Release and Vasodilatation in Guinea Pig M. Jesus Alonso, Jesus Mann and Carotid Arteries Mercedes Salaices BEHAVIORAL PHARMACOLOGY Relative Sensitivity to Naloxone of Multiple Indices of Opiate Gery Schulteis, Athina Markou, 1391 Withdrawal: A Quantitative Dose-Response Analysis Lisa H. Gold, Luis Stinus and George F. Koob Oligodeoxynudeotide Antisense to the D1 Dopamine Receptor Sui-Po Thang, Long-Wu Thou and 1462 mRNA Inhibits D1 Dopamine Receptor-Mediated Behaviors in Benjamin Weiss Normal Mice and in Mice Lesioned with 6-Hydroxydopamine CARDIOVASCULAR PHARMACOLOGY Chronic Nicotine Administration Does Not Affect Peripheral Then Li, Victor Barrios, John N. Buchholz, 1135 Vascular Reactivity in the Rat Thomas C. Glenn and Sue Piper Duckles Downloaded from Cyclic GMP Potentiation by WIN 58237, a Novel Cyclic Paul J. Silver, Ronald L. Dundore, 1143 Nucleotide Phosphodlesterase Inhibitor Donald C. Bode, Lawrence de Garavilla, R. Allan Buchholz, Glenn Van Ailer, Linda T. Hamel, Edward Bacon, Baldev Singli, George Y. Lasher, Dennis Hiasta and Edward D. Pagani Acute Effects of Ethanol on Cardiac Output and Its Abdel A. Abdel-Rabman 1150 jpet.aspetjournals.org Derivatives in Spontaneously Hypertensive and Normotensive Rats Unmasking of Activated Histamine H3-Receptors in Michiaki Imamura, Enzo Poli, 1259 Myocardlal Ischemia: Their Role as Regulators of Exocytotic Abimbola T. Omoniyi and Roberto Levi Noreplnephrine Release The Cardiac Effects of a Novel A1-Adenosine Receptor Agonist Luiz Belardinelli, Jiyuan Lu, Dunn Dennis, 1371 In Guinea Pig Isolated Heart Jeffrey Martens and John C. Shryock at ASPET Journals on October 2, 2021 Effects of Felodipine on Left Ventricular Systolic and Diastolic Che-Ping Cheng, Knut Pettersson and 1409 Performance in Congestive Heart Failure William C. Utile Characterization of PD 121981- and CGP 42112-Induced Ki Whan Hong, Byung Yong Rhixn, 1591 Unmasking of Low Concentration Effects of Anglotensin II in Yung Woo Shin and Sung-Eun Yoo Rabbit Abdominal Aorta -.. Furosemide Enhances the Release of Endothelial Kinins, Nitric Gabriele Wiemer, Edwin Fink, 1611 Oxide and Prostacydlin Wolfgang Linz, Max Hropot, Bernward A. Sch#{246}lkensand Paulus Wohlfart A Possible Mechanism of Action of a New Potassium Channel Sumio Matzno, Maid Gohda, 1666 Opener, AL0671, on Lipid Metabolism In Obese Zucker Rats Masahiro Eda, Hajime Ebisu, Shusei Uno, Naomichi Ishida, Norifumi Nakamura and Kouichi Yamanouchi CELLULAR AND MOLECULAR PHARMACOLOGY Isoflurane Reduces Ca4 Channel Current and Accelerates Dixon W. Wilde 1159 Current Decay in Guinea Pig Portal Vein Smooth Muscle Cells Electrophyslological and Radloligand Binding Studies of Nathalie Lepretre, Serge Arnaudeau, 1209 Elgodipine and Derivatives In Portal Vein Myocytes Jean Mironneau, Lala Rakotoarisoa, Chantal Mironneau and Alvaro Galiano Inhibition by Nickel of Endothelin-1-Induced Tension and Suraj S. Shetty and Dominick DelGrande 1223 Associated Ca Movements In Rabbit Aorta Influence of Cell Type upon the Desensitization of the Archana Chaudhry and 1253 fi3-Adrenerglc Receptor James G. Granneman Alaproclate Acts as a Potent, Reversible and Noncompetitive Anneli Wilkinson, Michael Courtney, 1314 Antagonist of the NMDA Receptor Coupled Ion Flow Anita Westhnd-Danielsson, Gerd Hailnemo and Karl E. 0. Akerman Contents continued on ill Contents continued from ii Effects of a New Class of Calcium Antagonists, 5R33557 Georges Romey and Michel Lazdunski 1348 (Fantofarone) and SR33805, on Neuronal Voltage-Activated Ca’ Channels Ca Mobifization Mediated by Endothelin ETA Receptor In Ken-Ichi Amano, Masatoshi Hori, 1359 Endothelium of Rabbit Aortic Valve Hiroshi Ozaki, Yuzuru Matsuda and Hideaki Karaki The Ca-Channel Blocker Ro 40-5967 Blocks Differently G. Mehrke, X. G. Zong, V. Flockerzi and 1483 T-Type and L-Type Ca Channels F. Hofinann The Novel A4,ha-2 Adrenergic Radloligand [3H]-MK912 is Staffan Uhl#{233}n,Amy C. Porter and 1558 Alpha-2C Selective among Human Alpha.2A, Alpha-2B and Richard R. Neubig Alpha.2C Adrenoceptors Mechanisms of Up-Regulation of Dopamine D2 Receptors by Theresa M. Filtz, Wei Guan, 1574 Agornsts and Antagonists in Transfected HEK-293 Cells Roman P. Artymyshyn, Mary Pacheco, Christine Ford and Perry B. Molinoff Disruption of GABA-Dependent Chloride Flux by Cyclodlenes Anna Pom#{233}s,Eduard RodrIguez-Faire and 1616 and Hexachiorocyclohexanes In Primary Cultures of Cortical Cristina Suflol Neurons Downloaded from ChEMOTHERAPY Decreased Intracellular Compartmentalization of Doxorubicin Margaret S. Dordal, Marisa Jackson-Stone, 1286 In Cell Lines Expressing P.Glycoproteln Amy C. Ho, Jane N. Winter and Arthur J. Atkinson, Jr. Enhancement by O6-Benzyl-N-Acetylguanosine Derivatives of Catherine Cussac, Maryse Rapp, 1353 jpet.aspetjournals.org Chioroethylnitrosourea Antitumor Action in Emmanuelle Mounetou, Chioroethylnitrosourea-Resistant Human Malignant Jean Claude Madelinont, Melanocytes Jean Claude Maurizis, Denise Godeneche, Jean Michel Dupuy, Jacques Sauzieres, Jean Paul Baudry and Annie Veyre DEVELOPMENTAL PHARMACOLOGY Antitumor Activity of a Medium-Chain Triglyceride Solution Shigeo Yanai, Hiroaki Okada, 1267 at ASPET Journals on October 2, 2021 of the Angiogenesis Inhibitor TNP-470 (AGM-1470) When Masafumi Misaki, Kazuhiro Saito, Administered Via the Hepatic Artery to Rats Bearing Walker Yuji Kuge, Yasuaki Ogawa and 256 Carcinosarcoma In the Liver Hajime Toguchi Neonatal HypoxIa: Early Neurotransmltter Responses and the Dimitri Krajnc, Trina A. Wemlinger, 1299 Consequences of Treatment with GM1 Ganglioside Norton H. Neff and Maria Hadjiconstantinou Potentlation of 51A Receptor-Mediated Neuroendocrine George Battaglia and Theresa M. Cabrera 1453 Responses In Male but not Female Rat Progeny after Prenatal Cocaine: Evidence for Gender Differences DRUG METABOLISM AND DISPOSITION Maternal and Fetal Brain and Plasma Levels of Cocaine and Susan E. Robinson, E. Karl Enters, 1234 Benzoylecgonlne After Acute or Chronic Maternal Intravenous George F. Jackson, Vernon M. Chinchilli, Administration
Load more

Recommended publications
  • Addictions and the Brain
    9/18/2012 Addictions and the Brain TAAP Conference September 14, 2012 Acknowledgements • La Hacienda Treatment Center • American Society of Addiction Medicine • National Institute of Drug Abuse © 2012 La Hacienda Treatment Center. All rights reserved. 1 9/18/2012 Definition • A primary, progressive biochemical, psychosocial, genetically transmitted chronic disease of relapse who’s hallmarks are denial, loss of control and unmanageability. DSM IV Criteria for dependency: At least 3 of the 7 below 1. Withdrawal 2. Tolerance 3. The substance is taken in larger amounts or over a longer period than was intended. 4. There is a persistent desire or unsuccessful efforts to cut down or control substance use. 5. A great deal of time is spent in activities necessary to obtain the substance, use the substance, or recover from its effects. 6. Important social, occupational, or recreational activities are given up or reduced because of the substance use. 7. The substance use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance. © 2012 La Hacienda Treatment Center. All rights reserved. 2 9/18/2012 Dispute between behavior and disease Present understanding of the Hypothalamus location of the disease hypothesis. © 2012 La Hacienda Treatment Center. All rights reserved. 3 9/18/2012 © 2012 La Hacienda Treatment Center. All rights reserved. 4 9/18/2012 © 2012 La Hacienda Treatment Center. All rights reserved. 5 9/18/2012 Dispute regarding behavior versus disease © 2012 La Hacienda Treatment Center. All rights reserved. 6 9/18/2012 © 2012 La Hacienda Treatment Center.
    [Show full text]
  • Euphoric Non-Fentanil Novel Synthetic Opioids on the Illicit Drugs Market
    Forensic Toxicology (2019) 37:1–16 https://doi.org/10.1007/s11419-018-0454-5 REVIEW ARTICLE The search for the “next” euphoric non‑fentanil novel synthetic opioids on the illicit drugs market: current status and horizon scanning Kirti Kumari Sharma1,2 · Tim G. Hales3 · Vaidya Jayathirtha Rao1,2 · Niamh NicDaeid4,5 · Craig McKenzie4 Received: 7 August 2018 / Accepted: 11 November 2018 / Published online: 28 November 2018 © The Author(s) 2018 Abstract Purpose A detailed review on the chemistry and pharmacology of non-fentanil novel synthetic opioid receptor agonists, particularly N-substituted benzamides and acetamides (known colloquially as U-drugs) and 4-aminocyclohexanols, developed at the Upjohn Company in the 1970s and 1980s is presented. Method Peer-reviewed literature, patents, professional literature, data from international early warning systems and drug user fora discussion threads have been used to track their emergence as substances of abuse. Results In terms of impact on drug markets, prevalence and harm, the most signifcant compound of this class to date has been U-47700 (trans-3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide), reported by users to give short- lasting euphoric efects and a desire to re-dose. Since U-47700 was internationally controlled in 2017, a range of related compounds with similar chemical structures, adapted from the original patented compounds, have appeared on the illicit drugs market. Interest in a structurally unrelated opioid developed by the Upjohn Company and now known as BDPC/bromadol appears to be increasing and should be closely monitored. Conclusions International early warning systems are an essential part of tracking emerging psychoactive substances and allow responsive action to be taken to facilitate the gathering of relevant data for detailed risk assessments.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20100227876A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0227876 A1 Rech (43) Pub. Date: Sep. 9, 2010 (54) METHODS OF REDUCING SIDE EFFECTS Publication Classi?cation OF ANALGESICS (51) Int CL A61K 31/485 (2006.01) A61K 31/40 (2006.01) (75) Inventor: Richard H. Rech, Okemos, MI A61K 31/445 (2006-01) (Us) A61K 31/439 (2006.01) (52) US. Cl. ........................ .. 514/282; 514/409; 514/329 (57) ABSTRACT Correspondence Address: The invention provides for compositions and methods of MARSHALL, GERSTEIN & BORUN LLP reducing pain in a subject by administering a combination of 233 SOUTH WACKER DRIVE, 6300 WILLIS mu-opioid receptor agonist, kappal-opioid receptor agonist TOWER and a nonselective opioid receptor antagonist in amounts CHICAGO, IL 60606-6357 (US) effective to reduce pain and ameliorate an adverse side effect of treatment combining opioid-receptor agonists. The inven tion also provides for methods of enhancing an analgesic effect of treatment With an opioid-receptor agonist in a sub (73) Assignee: RECHFENSEN LLP, RidgeWood, ject suffering from pain While reducing an adverse side effect NJ (US) of the treatment. The invention also provides for methods of reducing the hyperalgesic effect of treatment With an opioid receptor agonist in a subject suffering from pain While reduc ing an adverse side effect of the treatment. The invention (21) Appl. No.: 12/399,629 further provides for methods of promoting the additive anal gesia of pain treatment With an opioid-receptor agonist in a subject in need While reducing an adverse side effect of the (22) Filed: Mar.
    [Show full text]
  • Opioid Receptorsreceptors
    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
    [Show full text]
  • Measures and CDS for Safer Opioid Prescribing: a Literature Review
    Measures and CDS for Safer Opioid Prescribing: A Literature Review Measures and CDS for Safer Opioid Prescribing: A Literature Review Executive Summary The U.S. opioid epidemic continues to pose significant challenges for patients, families, clinicians, and public health policy. Opioids are responsible for an estimated 315,000 deaths (from 1999 to 2016) and have caused 115 deaths per day.1 In 2017, the U.S. Department of Health and Human Services declared the opioid epidemic a public health crisis.2 The total economic burden of opioid abuse in the United States has been estimated to be $78.5 billion per year.3 Although providing care for chronic opioid users is important, equally vital are efforts to prevent so-called opioid-naïve patients (patients with no history of opioid use) from developing regular opioid use, misuse, or abuse. However, much remains unclear regarding what role clinician prescribing habits play and what duration or dose of opioids may safely be prescribed without promoting long-term use.4,5 In 2013, ECRI Institute convened the Partnership for Health IT Patient Safety, and its component, single-topic-focused workgroups followed. For this subject, the Electronic Health Record Association (EHRA): Measures and Clinical Decision Support (CDS) for Safer Opioid Prescribing workgroup included members from the Healthcare Information and Management Systems Society (HIMSS) EHRA and the Partnership team. The project was oriented towards exploring methods to enable a synergistic cycle of performance measurement and identifying electronic health record (EHR)/health information technology (IT)–enabled approaches to support healthcare organizations’ ability to assess and measure opioid prescribing.
    [Show full text]
  • BBC Program 2016.Pages
    March 5-6, 2016 La Quinta Inn & Suites Medical Center San Antonio, TX Behavior, Biology, and Chemistry: Translational Research in Addiction BBC 2016 BBC Publications BBC 2011 Stockton Jr SD and Devi LA (2012) Functional relevance of μ–δ opioid receptor heteromerization: A Role in novel signaling and implications for the treatment of addiction disorders: From a symposium on new concepts in mu-opioid pharmacology. Drug and Alcohol Dependence Mar 1;121(3):167-72. doi: 10.1016/j.drugalcdep.2011.10.025. Epub 2011 Nov 23 Traynor J (2012) μ-Opioid receptors and regulators of G protein signaling (RGS) proteins: From a sym- posium on new concepts in mu-opioid pharmacology. Drug and Alcohol Dependence Mar 1;121(3): 173-80. doi: 10.1016/j.drugalcdep.2011.10.027. Epub 2011 Nov 29 Lamb K, Tidgewell K, Simpson DS, Bohn LM and Prisinzano TE (2012) Antinociceptive effects of herkinorin, a MOP receptor agonist derived from salvinorin A in the formalin test in rats: New concepts in mu opioid receptor pharmacology: From a symposium on new concepts in mu-opioid pharma- cology. Drug and Alcohol Dependence Mar 1;121(3):181-8. doi: 10.1016/j.drugalcdep.2011.10.026. Epub 2011 Nov 26 Whistler JL (2012) Examining the role of mu opioid receptor endocytosis in the beneficial and side-ef- fects of prolonged opioid use: From a symposium on new concepts in mu-opioid pharmacology. Drug and Alcohol Dependence Mar 1;121(3):189-204. doi: 10.1016/j.drugalcdep.2011.10.031. Epub 2012 Jan 9 BBC 2012 Zorrilla EP, Heilig M, de Wit, H and Shaham Y (2013) Behavioral, biological, and chemical perspectives on targeting CRF1 receptor antagonists to treat alcoholism.
    [Show full text]
  • 212102Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 212102Orig1s000 OTHER REVIEW(S) Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research | Office of Surveillance and Epidemiology (OSE) Epidemiology: ARIA Sufficiency Date: June 29, 2020 Reviewer: Silvia Perez-Vilar, PharmD, PhD Division of Epidemiology I Team Leader: Kira Leishear, PhD, MS Division of Epidemiology I Division Director: CAPT Sukhminder K. Sandhu, PhD, MPH, MS Division of Epidemiology I Subject: ARIA Sufficiency Memo for Fenfluramine-associated Valvular Heart Disease and Pulmonary Arterial Hypertension Drug Name(s): FINTEPLA (Fenfluramine hydrochloride, ZX008) Application Type/Number: NDA 212102 Submission Number: 212102/01 Applicant/sponsor: Zogenix, Inc. OSE RCM #: 2020-953 The original ARIA memo was dated June 23, 2020. This version, dated June 29, 2020, was amended to include “Assess a known serious risk” as FDAAA purpose (per Section 505(o)(3)(B)) to make it consistent with the approved labeling. The PMR development template refers to the original memo, dated June 23, 2020. Page 1 of 13 Reference ID: 46331494640015 EXECUTIVE SUMMARY (place “X” in appropriate boxes) Memo type -Initial -Interim -Final X X Source of safety concern -Peri-approval X X -Post-approval Is ARIA sufficient to help characterize the safety concern? Safety outcome Valvular Pulmonary heart arterial disease hypertension (VHD) (PAH) -Yes -No X X If “No”, please identify the area(s) of concern. -Surveillance or Study Population X X -Exposure -Outcome(s) of Interest X X -Covariate(s) of Interest X X -Surveillance Design/Analytic Tools Page 2 of 13 Reference ID: 46331494640015 1.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0245287 A1 Holaday Et Al
    US 20110245287A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0245287 A1 Holaday et al. (43) Pub. Date: Oct. 6, 2011 (54) HYBRD OPOD COMPOUNDS AND Publication Classification COMPOSITIONS (51) Int. Cl. A6II 3/4748 (2006.01) C07D 489/02 (2006.01) (76) Inventors: John W. Holaday, Bethesda, MD A6IP 25/04 (2006.01) (US); Philip Magistro, Randolph, (52) U.S. Cl. ........................................... 514/282:546/45 NJ (US) (57) ABSTRACT Disclosed are hybrid opioid compounds, mixed opioid salts, (21) Appl. No.: 13/024,298 compositions comprising the hybrid opioid compounds and mixed opioid salts, and methods of use thereof. More particu larly, in one aspect the hybrid opioid compound includes at (22) Filed: Feb. 9, 2011 least two opioid compounds that are covalently bonded to a linker moiety. In another aspect, the hybrid opioid compound relates to mixed opioid salts comprising at least two different Related U.S. Application Data opioid compounds or an opioid compound and a different active agent. Also disclosed are pharmaceutical composi (60) Provisional application No. 61/302,657, filed on Feb. tions, as well as to methods of treating pain in humans using 9, 2010. the hybrid compounds and mixed opioid salts. Patent Application Publication Oct. 6, 2011 Sheet 1 of 3 US 2011/0245287 A1 Oral antinociception of morphine, oxycodone and prodrug combinations in CD1 mice s Tigkg -- Morphine (2.80 mg/kg (1.95 - 4.02, 30' peak time -- (Oxycodone (1.93 mg/kg (1.33 - 2,65)) 30 peak time -- Oxy. Mor (1:1) (4.84 mg/kg (3.60 - 8.50) 60 peak tire --MLN 2-3 peak, effect at a hors 24% with closes at 2.5 art to rigg - D - MLN 2-45 (6.60 mg/kg (5.12 - 8.51)} 60 peak time Figure 1.
    [Show full text]
  • WO 2012/109445 Al 16 August 2012 (16.08.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/109445 Al 16 August 2012 (16.08.2012) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/485 (2006.01) A61P 25/04 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/US20 12/024482 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (22) International Filing Date: HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, ' February 2012 (09.02.2012) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 13/024,298 9 February 201 1 (09.02.201 1) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): QRX- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, PHARMA LTD.
    [Show full text]
  • Evaluation of Biased and Balanced Salvinorin a Analogs in Preclinical Models of Pain
    fnins-14-00765 July 18, 2020 Time: 20:26 # 1 ORIGINAL RESEARCH published: 21 July 2020 doi: 10.3389/fnins.2020.00765 Evaluation of Biased and Balanced Salvinorin A Analogs in Preclinical Models of Pain Kelly F. Paton1, Andrew Biggerstaff1, Sophia Kaska2, Rachel S. Crowley3, Anne C. La Flamme1,4, Thomas E. Prisinzano2,3 and Bronwyn M. Kivell1* 1 School of Biological Sciences, Centre for Biodiscovery, Faculty of Science, Victoria University of Wellington, Wellington, New Zealand, 2 Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, United States, 3 Department of Medicinal Chemistry, School of Pharmacy, The University of Kansas, Lawrence, KS, United States, 4 Malaghan Institute of Medical Research, Wellington, New Zealand In the search for safer, non-addictive analgesics, kappa opioid receptor (KOPr) agonists are a potential target, as unlike mu-opioid analgesics, they do not have abuse potential. Salvinorin A (SalA) is a potent and selective KOPr agonist, however, clinical utility is limited by the short duration of action and aversive side effects. Biasing KOPr signaling toward G-protein activation has been highlighted as a key cellular mechanism to reduce the side effects of KOPr agonists. The present study investigated KOPr signaling bias and the acute antinociceptive effects and side effects of two novel analogs of SalA, Edited by: 16-Bromo SalA and 16-Ethynyl SalA. 16-Bromo SalA showed G-protein signaling bias, Dominique Massotte, whereas 16-Ethynyl SalA displayed balanced signaling properties. In the dose-response Université de Strasbourg, France tail-withdrawal assay, SalA, 16-Ethynyl SalA and 16-Bromo SalA were more potent than Reviewed by: Mariana Spetea, the traditional KOPr agonist U50,488, and 16-Ethynyl SalA was more efficacious.
    [Show full text]
  • Diverse Kappa Opioid Receptor Agonists: Relationships Between Signaling and Behavior
    Rockefeller University Digital Commons @ RU Student Theses and Dissertations 2020 Diverse Kappa Opioid Receptor Agonists: Relationships Between Signaling and Behavior Amelia Dunn Follow this and additional works at: https://digitalcommons.rockefeller.edu/ student_theses_and_dissertations Part of the Life Sciences Commons DIVERSE KAPPA OPIOID RECEPTOR AGONISTS: RELATIONSHIPS BETWEEN SIGNALING AND BEHAVIOR A Thesis Presented to the Faculty of The Rockefeller University in Partial Fulfillment of the Requirements for the degree of Doctor of Philosophy by Amelia Dunn June 2020 © Copyright by Amelia Dunn 2020 Diverse Kappa Opioid Receptor Agonists: Relationships Between Signaling and Behavior Amelia Dunn, Ph.D. The Rockefeller University 2020 The opioid system, comprised mainly of the three opioid receptors (kappa, mu and delta) and their endogenous neuropeptide ligands (dynorphin, endorphin and enkephalin, respectively), mediates mood and reward. Activation of the mu opioid receptor is associated with positive reward and euphoria, while activation of the kappa opioid receptor (KOR) has the opposite effect. Activation of the KOR causes a decrease in dopamine levels in reward-related regions of the brain, and can block the rewarding effects of various drugs of abuse, making it a potential drug target for addictive diseases. KOR agonists are of particular interest for the treatment of cocaine and other psychostimulant addictions, because there are currently no available medications for these diseases. Studies in humans and animals, however, have shown that activation of the KOR also causes negative side effects such as hallucinations, aversion and sedation. Several strategies are currently being employed to develop KOR agonists that block the rewarding effects of drugs of abuse with fewer side effects, including KOR agonists with unique pharmacology.
    [Show full text]
  • Stress-Induced Reinstatement of Drug Seeking: 20 Years of Progress
    Neuropsychopharmacology REVIEWS (2016) 41, 335–356 © 2016 American College of Neuropsychopharmacology All rights reserved 0893-133X/16 REVIEW ..................................................................................................................................................................... www.neuropsychopharmacologyreviews.org 335 Stress-Induced Reinstatement of Drug Seeking: 20 Years of Progress ,1 1 2 2 ,3 John R Mantsch* , David A Baker , Douglas Funk ,AnhDLê and Yavin Shaham* 1 2 Department of Biomedical Sciences, Marquette University, Milwaukee, Wisconsin, USA; Center for Addiction and Mental 3 Health, Campbell Family Mental Health Research Institute, University of Toronto, Toronto, ON, Canada; Intramural Research Program, NIDA-NIH, Baltimore, MD, USA In human addicts, drug relapse and craving are often provoked by stress. Since 1995, this clinical scenario has been studied using a rat model of stress-induced reinstatement of drug seeking. Here, we first discuss the generality of stress-induced reinstatement to different drugs of abuse, different stressors, and different behavioral procedures. We also discuss neuropharmacological mechanisms, and brain areas and circuits controlling stress-induced reinstatement of drug seeking. We conclude by discussing results from translational human laboratory studies and clinical trials that were inspired by results from rat studies on stress-induced reinstatement. Our main conclusions are (1) The phenomenon of stress-induced reinstatement, first shown with an intermittent footshock
    [Show full text]